Porfimer Sodium

Generic Name: Porfimer Sodium

Brand Names: Photofrin

Drug Type: Small Molecule

CAS Number: 87806-31-3

Unique Ingredient Identifier: Y3834SIK5F

Background: The purified component of hematoporphyrin derivative, it consists of a mixture of oligomeric porphyrins. It is used in photodynamic therapy (hematoporphyrin photoradiation); to treat malignant lesions with visible light and experimentally as an antiviral agent. It is the first drug to be approved in the use of photodynamic therapy in the United States.

Indication: 临床上用于对不能用手术及其他根治疗法的肺、子宫颈癌或需非手术治疗的患者，在内镜下能观察到病灶的全貌、可能进行激光照射的下列疾病：早期肺癌（0期或Ⅰ期）、浅表性食管癌、浅表性早期胃癌、宫颈癌初期及发育异常。

Associated Conditions: Barrett's Esophagus, Esophageal Cancer, Completely obstructive Non-small cell lung cancer, Microinvasive endobrachial Non-small cell lung cancer, Partially obstructive Non-small cell lung cancer

Clinical Trials

Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients With Non-small Cell Lung Cancer With Pleural Disease

Phase 1

Suspended

Conditions: Lung Non-Small Cell Carcinoma
Pleural Disorder

Interventions: Drug: Porfimer Sodium
Procedure: Video-Assisted Thoracic Surgery
Drug: Photodynamic Therapy
Device: Intraoperative PDT

First Posted Date: 2021-04-08

Last Posted Date: 2024-06-04

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 16

Registration Number: NCT04836429

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Novel Light Delivery Methods for Lung Cancer Photodynamic Therapy - A Pilot Study

Early Phase 1

Conditions: Lung Metastasis
Non-small Cell Lung Cancer (NSCLC)

Interventions: Drug: Porfimer sodium
Drug: Ethiodized oil
Procedure: Novel light delivery methods of photodynamic therapy
Device: Fiber optic

First Posted Date: 2021-02-15

Last Posted Date: 2021-02-15

Lead Sponsor: Taoyuan General Hospital

Target Recruit Count: 3

Registration Number: NCT04753918

Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer

Phase 1

Terminated

Conditions: Locally Advanced Lung Carcinoma
Solid Tumor
Non-Small Cell Lung Carcinoma
Small Cell Lung Carcinoma
Stage III Lung Cancer AJCC v8
Stage IIIB Lung Cancer AJCC v8
Stage IIIA Lung Cancer AJCC v8
Stage IIIC Lung Cancer AJCC v8

Interventions: Drug: Porfimer Sodium
Procedure: Ultrasound-Guided Transbronchial Needle-Delivered Interstitial Photodynamic Therapy

First Posted Date: 2018-11-08

Last Posted Date: 2025-04-16

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 19

Registration Number: NCT03735095

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Porfimer Sodium Interstitial Photodynamic Therapy With or Without Standard of Care Chemotherapy in Treating Patients With Locally Advanced or Recurrent Head and Neck Cancer

Phase 1

Terminated

Conditions: Locally Advanced Head and Neck Carcinoma
Recurrent Head and Neck Carcinoma

Interventions: Biological: Nivolumab
Drug: Porfimer Sodium
Procedure: Interstitial Illumination Photodynamic Therapy
Other: Quality of Life Assessment

First Posted Date: 2018-11-01

Last Posted Date: 2025-03-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 5

Registration Number: NCT03727061

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Light Dosimetry for Photodynamic Therapy With Porfimer Sodium in Treating Participants With Malignant Mesothelioma or Non-Small Cell Lung Cancer With Pleural Disease Undergoing Surgery

Phase 1

Active, not recruiting

Conditions: Non-Small Cell Lung Carcinoma
Pleural Disorder
Malignant Mesothelioma

Interventions: Device: Light Dosimetry for Intranoperative Therapy
Procedure: Photodynamic Therapy
Drug: Porfimer Sodium

First Posted Date: 2018-09-19

Last Posted Date: 2025-05-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 9

Registration Number: NCT03678350

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Safety of PDT-Photofrin® Prior to Lung Surgery

Phase 1

Completed

Conditions: Lung Cancer
Lung Cancer Metastatic

Interventions: Drug: Porfimer Sodium
Device: Fiber optic

First Posted Date: 2017-11-17

Last Posted Date: 2020-01-13

Lead Sponsor: Concordia Laboratories Inc.

Target Recruit Count: 10

Registration Number: NCT03344861

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
University of Colorado, Denver, Colorado, United States

and more 5 locations

Feasibility Study of Using Navigational Bronchoscopy to Perform PDT-Photofrin® in Unresectable Peripheral Lung Cancer

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer (NSCLC)
Lung Metastasis

Interventions: Drug: Porfimer sodium
Device: Fiber optic

First Posted Date: 2016-09-27

Last Posted Date: 2020-03-04

Lead Sponsor: Concordia Laboratories Inc.

Target Recruit Count: 5

Registration Number: NCT02916745

Locations: 🇺🇸
University of Florida, Gainesville, Florida, United States
🇺🇸
Southeastern Regional Medical Center, Atlanta, Georgia, United States
🇺🇸
Providence Medical Research Center, Spokane, Washington, United States

and more 4 locations

Phase II Trial of Radical Pleurectomy With or Without Intraoperative PDT for Malignant Pleural Mesothelioma

Phase 2

Active, not recruiting

Conditions: Epitheliod Malignant Pleural Mesothelioma

Interventions: Radiation: Photodynamic Therapy
Radiation: Chemotherapy
Procedure: Radical Pleurectomy
Drug: Photofrin 2.0 mg/kg

First Posted Date: 2014-06-03

Last Posted Date: 2024-12-12

Lead Sponsor: Abramson Cancer Center at Penn Medicine

Target Recruit Count: 52

Registration Number: NCT02153229

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States

Photodynamic Therapy During Surgery in Treating Patients With Pleural Malignancy

Not Applicable

Withdrawn

Conditions: Stage IIIB Non-small Cell Lung Cancer
Stage III Malignant Mesothelioma
Stage IV Non-small Cell Lung Cancer
Stage IV Malignant Mesothelioma

Interventions: Drug: porfimer sodium
Procedure: therapeutic conventional surgery
Drug: photodynamic therapy

First Posted Date: 2014-04-08

Last Posted Date: 2019-03-21

Lead Sponsor: Ohio State University Comprehensive Cancer Center

Registration Number: NCT02106559

Interstitial Photodynamic Therapy in Treating Patients With Recurrent Head and Neck Cancer

Phase 2

Terminated

Conditions: Recurrent Lip and Oral Cavity Squamous Cell Carcinoma
Recurrent Metastatic Squamous Cell Carcinoma in the Neck With Occult Primary
Recurrent Laryngeal Squamous Cell Carcinoma
Recurrent Oropharyngeal Squamous Cell Carcinoma
Recurrent Oral Cavity Verrucous Carcinoma
Recurrent Laryngeal Verrucous Carcinoma
Tongue Carcinoma

Interventions: Other: Laboratory Biomarker Analysis
Drug: Photodynamic Therapy
Drug: Porfimer Sodium

First Posted Date: 2014-02-21

Last Posted Date: 2017-10-11

Lead Sponsor: Roswell Park Cancer Institute

Target Recruit Count: 3

Registration Number: NCT02068157

Locations: 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy